Acorda Therapeutics (ACOR) Misses Q2 EPS by $2.79

Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($3.15), $2.79 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $29.1 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold